Cargando...
Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism
Patients with chronic kidney disease often develop secondary hyperparathyroidism (SHPT), marked by high levels of circulating parathyroid hormone (PTH) and increased risk of morbidity and mortality. Patients with SHPT are treated with a therapeutic combination that commonly includes calcimimetics, w...
Guardado en:
| Publicado en: | Ther Apher Dial |
|---|---|
| Autores principales: | , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
John Wiley & Sons Australia, Ltd
2019
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7317959/ https://ncbi.nlm.nih.gov/pubmed/31486206 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1744-9987.13434 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|